Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:CPRX NASDAQ:MIRM NASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$2.35-2.1%$2.26$1.11▼$5.00$638.74M1.91.55 million shs1.35 million shsCPRXCatalyst Pharmaceuticals$21.12-1.0%$22.63$15.34▼$26.58$2.60B0.71.21 million shs999,536 shsMIRMMirum Pharmaceuticals$52.02+0.7%$49.71$36.20▼$54.78$2.56B0.94351,958 shs337,696 shsNAMSNewAmsterdam Pharma$21.28-2.4%$20.18$14.06▼$27.29$2.45B-0.03776,378 shs537,520 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-2.08%-6.75%0.00%+74.07%-49.89%CPRXCatalyst Pharmaceuticals-0.98%+0.72%-1.54%-14.98%+22.51%MIRMMirum Pharmaceuticals+0.66%+0.37%+5.97%+19.07%+28.29%NAMSNewAmsterdam Pharma-2.43%-9.83%+12.24%+6.24%+24.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics2.3438 of 5 stars3.52.00.00.00.63.30.6CPRXCatalyst Pharmaceuticals4.8982 of 5 stars3.61.00.03.94.03.33.8MIRMMirum Pharmaceuticals3.7376 of 5 stars3.60.00.04.22.91.70.6NAMSNewAmsterdam Pharma3.2139 of 5 stars4.41.00.00.01.55.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32296.60% UpsideCPRXCatalyst Pharmaceuticals 3.25Buy$32.8355.46% UpsideMIRMMirum Pharmaceuticals 3.13Buy$65.5025.91% UpsideNAMSNewAmsterdam Pharma 2.89Moderate Buy$41.3094.08% UpsideCurrent Analyst Ratings BreakdownLatest AUTL, MIRM, CPRX, and NAMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/17/2025NAMSNewAmsterdam PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$27.007/11/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/17/2025NAMSNewAmsterdam PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.006/12/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/12/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.006/10/2025NAMSNewAmsterdam PharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$44.006/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/4/2025NAMSNewAmsterdam PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.005/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$10.12M61.80N/AN/A$1.61 per share1.46CPRXCatalyst Pharmaceuticals$491.73M5.24$2.42 per share8.72$6.10 per share3.46MIRMMirum Pharmaceuticals$336.89M7.65N/AN/A$4.70 per share11.07NAMSNewAmsterdam Pharma$47.14M50.68N/AN/A$8.20 per share2.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/12/2025 (Estimated)CPRXCatalyst Pharmaceuticals$163.89M$1.5713.459.920.8736.91%42.45%36.59%8/6/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.88N/AN/AN/A-397.45%-37.34%-33.45%8/6/2025 (Estimated)Latest AUTL, MIRM, CPRX, and NAMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.2329N/AN/AN/A$12.92 millionN/A8/6/2025Q2 2025CPRXCatalyst Pharmaceuticals$0.57N/AN/AN/A$140.42 millionN/A8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31N/AN/AN/A$107.91 millionN/A8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52N/AN/AN/A$1.44 millionN/A5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A9.249.02CPRXCatalyst PharmaceuticalsN/A6.145.96MIRMMirum Pharmaceuticals1.323.223.04NAMSNewAmsterdam PharmaN/A19.9819.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CPRXCatalyst Pharmaceuticals79.22%MIRMMirum PharmaceuticalsN/ANAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CPRXCatalyst Pharmaceuticals10.40%MIRMMirum Pharmaceuticals14.36%NAMSNewAmsterdam Pharma20.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableMIRMMirum Pharmaceuticals14049.53 million42.42 millionOptionableNAMSNewAmsterdam Pharma4112.27 million88.87 millionOptionableAUTL, MIRM, CPRX, and NAMS HeadlinesRecent News About These CompaniesNewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically ...August 1 at 2:37 AM | bakersfield.comBNewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025July 30 at 8:25 AM | globenewswire.comNewAmsterdam Pharma (NAMS) Projected to Post Earnings on WednesdayJuly 30 at 5:29 AM | marketbeat.comBryce Point Capital LLC Invests $438,000 in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)July 28, 2025 | marketbeat.comNewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025July 24, 2025 | bakersfield.comBReadystate Asset Management LP Reduces Stock Position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)July 23, 2025 | marketbeat.comNewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025July 22, 2025 | globenewswire.comAtle Fund Management AB Cuts Stock Holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)July 19, 2025 | marketbeat.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Sold by Jennison Associates LLCJuly 19, 2025 | marketbeat.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells $1,019,879.36 in StockJuly 18, 2025 | marketbeat.comInsider Selling: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells 51,043 Shares of StockJuly 18, 2025 | marketbeat.comDouglas F. Kling Sells 47,569 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) StockJuly 18, 2025 | insidertrades.comGoldman Sachs Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Neutral RecommendationJuly 17, 2025 | msn.comNewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at The Goldman Sachs GroupJuly 17, 2025 | marketbeat.comJefferies Remains Bullish on NewAmsterdam Pharma (NAMS)July 16, 2025 | msn.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Buy" from AnalystsJuly 14, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 5.7% - Still a Buy?July 9, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Upgraded by Wall Street ZenJuly 5, 2025 | marketbeat.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Purchases 1,260 SharesJune 27, 2025 | insidertrades.comFirst Week of February 2026 Options Trading For NewAmsterdam Pharma (NAMS) - NasdaqJune 24, 2025 | nasdaq.comNewAmsterdam Pharma Company N.V. (NAMS) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUTL, MIRM, CPRX, and NAMS Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$2.35 -0.05 (-2.08%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.35 0.00 (-0.21%) As of 08/1/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Catalyst Pharmaceuticals NASDAQ:CPRX$21.12 -0.21 (-0.98%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.06 -0.05 (-0.26%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Mirum Pharmaceuticals NASDAQ:MIRM$52.02 +0.34 (+0.66%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$52.01 -0.01 (-0.02%) As of 08/1/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.NewAmsterdam Pharma NASDAQ:NAMS$21.28 -0.53 (-2.43%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.28 0.00 (0.00%) As of 08/1/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.